UCLA scientists engineer potent immune cells for “off-the-shelf” cancer immunotherapy

UCLA: Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence

A novel treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a phase III trial co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators.

March 29, 2024

Vol.50 No.13

Clinical Roundup

UCLA: Attacking metastatic prostate cancer early with combination treatment improves outcomes

A team of UCLA Health Jonsson Comprehensive Cancer Center investigators has shown the combination of a short course of powerful and intense hormonal therapy with targeted radiation is safe and effective in treating people with prostate cancer that has come back and has spread to other parts of the body.

March 22, 2024

Vol.50 No.12

Clinical Roundup

UCLA: Researchers uncover a potential genetic marker associated with better survival outcomes in head and neck cancer

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center showed for the first time that a gene usually linked to giant axonal neuropathy, a rare and severe neurological condition, also plays a role in inhibiting aggressive tumor cell growth in head and neck cancers.

March 08, 2024

Vol.50 No.10

Clinical Roundup

UCLA study: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.

February 23, 2024

Vol.50 No.08

In Brief

Mediget Teshome named chief of breast surgery at UCLA Health

Breast surgical oncologist Mediget Teshome was named chief of breast surgery and director of breast health at UCLA Health.

January 19, 2024

Vol.50 No.03

Clinical Roundup

UCLA study: High-dose radiotherapy + chemo effective in treating NSCLC

A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center showed that using high doses of radiation while integrating an ablative radiotherapy technique called stereotactic ablative radiotherapy concurrently with chemotherapy is safe and effective in treating people with locally advanced non-small cell lung cancer that is not suitable for surgery.

January 19, 2024

Vol.50 No.03

UCLA scientists engineer potent immune cells for “off-the-shelf” cancer immunotherapy

YOU MAY BE INTERESTED IN

UCLA: Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence

UCLA: Attacking metastatic prostate cancer early with combination treatment improves outcomes

UCLA: Researchers uncover a potential genetic marker associated with better survival outcomes in head and neck cancer

UCLA study: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

Mediget Teshome named chief of breast surgery at UCLA Health

UCLA study: High-dose radiotherapy + chemo effective in treating NSCLC

Renew today!

Subscriber content

Login